Vaccine Evidence Compendium

RSV vaccines

Efficacy and effectiveness estimates (e.g. against infection, disease, hospitalization, death), including in different populations

For maternal RSVPreF: Vaccine efficacy against RSV-positive severe medically-attended LRTI at 180 days after birth was 70 % (50.6, 82.5) and 49.2% (31.4, 62.8) against RSV-positive medically attended LRTI. 

For nirsevimab: Efficacy against medically attended RSV-associated LRTI was 79% (68.5, 86.1). Efficacy against hospitalization for RSV-associated LRTI was 80.6% (62.3, 90.1) and efficacy against severe hospitalized RSV-associated LRTI was 78.5% (48.8,91.0). ,   

Both products have been shown to have high, similar effectiveness when used in real-world situations.

Sources

  • Müller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. (2023). Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 388:1533–1534. doi:10.1056/NEJMc2214773. 

  • Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. (2020). Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 383:415–425. doi:10.1056/NEJMoa1913556. 

  • Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. (2023). Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 388:1451–1464. doi:10.1056/NEJMoa2216480.

Loading...